Review
[Anti-angiogenesis targeting drugs: a review]
[Article in
Chinese]
Affiliations
- PMID: 18423135
Item in Clipboard
Review
[Anti-angiogenesis targeting drugs: a review]
[Article in
Chinese]
Ai Zheng.
2008 Apr.
Free article
Abstract
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for cancer therapy. One of the key mediators of angiogenesis is vascular endothelial growth factor (VEGF), which is an appealing target for anticancer therapy. The development of anti-VEGF/VEGFR agents and the latest clinical data are reviewed, including bevacizumab as a monoclonal antibody to VEGF, sunitinib and sorafenib as VEGFR tyrosine kinase inhibitors, and IMC-1C11 as VEGFR monoclonal antibody.
Similar articles
-
Angiogenesis inhibitors in the treatment of lung cancer.Crit Rev Oncol Hematol. 2007 May;62(2):93-104. doi: 10.1016/j.critrevonc.2007.01.002. Epub 2007 Feb 15. Crit Rev Oncol Hematol. 2007. PMID: 17306557 Review.
-
Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.Clin Adv Hematol Oncol. 2003 Jan;1(1):41-8. Clin Adv Hematol Oncol. 2003. PMID: 16227959 Review.
-
Anti-angiogenic therapy against gastrointestinal tract cancers.Jpn J Clin Oncol. 2009 Sep;39(9):543-51. doi: 10.1093/jjco/hyp062. Epub 2009 Jun 16. Jpn J Clin Oncol. 2009. PMID: 19531544 Review.
-
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.Clin Cancer Res. 2006 Nov 1;12(21):6573-84. doi: 10.1158/1078-0432.CCR-06-0831. Clin Cancer Res. 2006. PMID: 17085673
-
Angiogenesis inhibition in solid tumors.Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
